GRI Bio, Inc. (GRI)
1.93
+0.09
(+4.89%)
USD |
NASDAQ |
Sep 18, 16:00
1.90
-0.03
(-1.55%)
After-Hours: 20:00
GRI Bio Enterprise Value : -6.684M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | -6.684M |
| September 17, 2026 | -6.881M |
| September 16, 2026 | -6.946M |
| September 15, 2026 | -6.924M |
| September 14, 2026 | -6.771M |
| September 11, 2026 | -6.749M |
| September 10, 2026 | -6.662M |
| September 09, 2026 | -6.968M |
| September 08, 2026 | -6.531M |
| September 04, 2026 | -4.607M |
| September 03, 2026 | -5.897M |
| September 02, 2026 | -6.531M |
| September 01, 2026 | -6.728M |
| August 31, 2026 | -6.706M |
| August 28, 2026 | -6.706M |
| August 27, 2026 | -6.378M |
| August 26, 2026 | -6.728M |
| August 25, 2026 | -6.618M |
| August 24, 2026 | -6.990M |
| August 21, 2026 | -7.296M |
| August 20, 2026 | -7.252M |
| August 19, 2026 | -7.121M |
| August 18, 2026 | -7.165M |
| August 17, 2026 | -7.121M |
| August 14, 2026 | -7.252M |
| Date | Value |
|---|---|
| August 13, 2026 | -7.034M |
| August 12, 2026 | -6.640M |
| August 11, 2026 | -6.094M |
| August 10, 2026 | -7.187M |
| August 07, 2026 | -7.689M |
| August 06, 2026 | -7.514M |
| August 05, 2026 | -7.558M |
| August 04, 2026 | -7.427M |
| August 03, 2026 | -7.755M |
| July 31, 2026 | -7.886M |
| July 30, 2026 | -7.821M |
| July 29, 2026 | -7.689M |
| July 28, 2026 | -7.777M |
| July 27, 2026 | -7.842M |
| July 24, 2026 | -7.733M |
| July 23, 2026 | -7.624M |
| July 22, 2026 | -7.668M |
| July 21, 2026 | -7.602M |
| July 20, 2026 | -7.689M |
| July 17, 2026 | -7.624M |
| July 16, 2026 | -7.536M |
| July 15, 2026 | -7.362M |
| July 14, 2026 | -7.471M |
| July 13, 2026 | -7.362M |
| July 10, 2026 | -7.099M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.980B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.643M |
| Total Expenses (Quarterly) | 1.643M |
| EPS Diluted (Quarterly) | -0.9103 |
| Earnings Yield | -2.27K% |
| Normalized Earnings Yield | -2266.33 |